Summary of iRhythm Technologies, Inc. Q3 2025 Earnings Call

1Key Financial Results and Metrics:

Revenue: $192.9 million, a 31% increase year-over-year.

Adjusted EBITDA: $21.6 million, with an adjusted EBITDA margin of 11.2%.

Gross Margin: 71.1%, up 230 basis points from Q3 2024.

Adjusted Net Loss: $2 million, or $0.06 per share, significantly improved from a loss of $39.2 million ($1.26 per share) in Q3 2024.

Free Cash Flow: Positive free cash flow of $20 million for the quarter; expected to be free cash flow positive for the full year 2025 for the first time in the company's history.

Cash Position: $565.2 million in unrestricted cash and short-term investments.

2Strategic Updates and Business Highlights:

Continued strong performance in both Zio Monitor and Zio AT, with record account openings and EHR integrations.

76 of the top 100 customers are now EHR integrated, leading to an average 25% increase in monitoring volume post-integration.

Expansion into primary care is ongoing, with Zio being utilized as a rule-in or rule-out tool for early intervention.

New partnerships in innovative channels are growing, with 18 active partner accounts focused on undiagnosed arrhythmias.

Development of Zio MCT (mobile cardiac telemetry) is underway, with a 510(k) filing submitted to the FDA.

Advancements in AI capabilities for identifying undiagnosed patients at risk of cardiac arrhythmias through partnerships, including with Lucem Health.

3Forward Guidance and Outlook:

Full-year 2025 revenue guidance raised to $735 million to $740 million, reflecting 24% to 25% year-over-year growth.

Adjusted EBITDA margin guidance increased to 8.25% to 8.75%.

Anticipation of continued strong growth in Q4, though a slight deceleration is expected due to strong Q4 2024 performance.

Long-term gross margin target remains at 72% to 73% by 2027, with expectations for ongoing margin improvement.

4Bad News, Challenges, or Points of Concern:

The company is still navigating FDA remediation efforts, with communication on timelines being limited due to the FDA shutdown.

The potential for MCT approval remains uncertain, leading to cautious guidance for 2026.

Competitive pressures persist, particularly from traditional Holter and event monitors, which still dominate a significant portion of the market.

5Notable Q&A Insights:

Management highlighted that new account growth is driven by the ability to onboard entire networks quickly, enhancing customer appeal.

The innovative partner channel is seeing varied sales cycles, with some partnerships taking over a year to scale while others are quicker.

The potential for Zio MCT to be downgradable to an event monitor was discussed, with management noting that not much AT business is currently unreimbursed.

The overlap between cardiac arrhythmias and sleep disorders was emphasized, with plans for future multi-sensing platform development to address both conditions. Overall, iRhythm Technologies reported a strong quarter with significant growth and positive cash flow, while also outlining strategic initiatives and navigating challenges related to FDA approvals and market competition.